Spruce Biosciences, Kaken Pharmaceutical sign deal for tildacerfont to treat CAH
As per the terms of the agreement, Spruce will get an upfront payment of $15m from Kaken. It will also be eligible to get further payments following the
Darovasertib is a potential first-in-class protein kinase C (PKC) inhibitor, and crizotinib is an investigational cMET inhibitor. The designation will allow the darovasertib / crizotinib development programme to
Under the deal, both entities will focus on discovering and developing new therapeutics based on small interfering RNA (siRNA) technology. The partnership will identify new therapeutic targets, which are